Office of The Director, National Institutes of Health; Notice of Meeting, 4492-4493 [2019-02433]
Download as PDF
<![CDATA[
4492
Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 11, 2019.
Natasha Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02424 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: ‘‘Treatment of Acute
Lymphoblastic Leukemia, T-Cell
Lymphoma, and Non-Small Cell Lung
Cancer Using the 4A10 Antibody and
Fragments Thereof’’
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patent Applications listed in the
Supplementary Information section of
this notice to Fannin Partners L.L.C.,
(‘‘Fannin’’) of Houston, Texas.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before March 4, 2019 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Lauren Nguyen-Antczak, Sr.
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, Rm. 1E530, MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240)–276–5530;
Facsimile: (240)-276–5504 Email:
lauren.nguyen-antczak@nih.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKBBV9HB2PROD with NOTICES
SUMMARY:
Intellectual Property
Entitled ‘‘IL–7R-alpha Specific
Antibodies for Treating Acute
Lymphoblastic Leukemia’’
(1) U.S. Provisional Patent
Application No. 62/238,612, filed
October 7, 2015, corresponding to NIH
Ref. No. E–247–2015/0–US–0;
(2) International Patent Application
No. PCT/US2016/055957, filed October
7, 2016, corresponding to NIH Ref. No.
E–247–2015/0–PCT–02;
VerDate Sep<11>2014
19:41 Feb 14, 2019
Jkt 247001
(3) Australian Patent Application No.
2016–335750, filed October 7, 2016,
corresponding to NIH Ref. No. E–247–
2015/0–AU–03;
(4) Canadian Patent Application No.
2997809, filed October 7, 2016,
corresponding to NIH Ref. No. E–247–
2015/0–CA–04;
(5) European Patent Application No.
16784678.1, filed October 7, 2016,
corresponding to NIH Ref. No. E–247–
2015/0–EP–05;
(6) U.S. Patent Application No. 15/
760,193, filed March 14, 2018,
corresponding to NIH Ref. No. E–247–
2015/0–US–07;
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be where patent
applications are filed and the field of
use may be limited to ‘‘Treatment of
acute lymphoblastic leukemia, T-cell
lymphoma, and non-small cell lung
cancer using the 4A10 antibody and
fragments thereof’’. Additional
licensable fields of use are available.
The subject technology is directed to
monoclonal antibodies (mAb) specific
for the alpha chain of the interleukin 7
receptor (IL–7Ra), and corresponding
antigen binding fragments, bispecific
antibodies, antibody drug conjugates,
and encoding nucleic acid thereof.
Specifically developed mAbs include
those called ‘‘4A10’’ and ‘‘2B8’’. In
certain embodiments, the 4A10
antibody can be administered to treat
acute lymphoblastic leukemia,
particularly those that arise from
aberrations in T-cell lineages.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Freedom of Information Act, 5 U.S.C.
552.
Dated: February 6, 2019.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2019–02442 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of The Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Advisory Committee to
the Director, National Institutes of
Health.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Advisory Committee
to the Director, National Institutes of Health.
Date: June 13, 2019.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: NIH Director’s Report, ACD
Working Group Reports, Other Business of
the Committee.
Place: National Institutes of Health,
Natcher Building, Conference Room D, 45
Center Drive, Bethesda, MD 20892.
Name of Committee: Advisory Committee
to the Director, National Institutes of Health.
Date: June 14, 2019.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: ACD Working Group Reports,
Other Business of the Committee.
Place: National Institutes of Health,
Natcher Building, Conference Room D, 45
Center Drive, Bethesda, MD 20892.
Contact Person: Gretchen Wood, Staff
Assistant, National Institutes of Health,
Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892,
301–496–4272, Woodgs@od.nih.gov.
Name of Committee: Advisory Committee
to the Director, National Institutes of Health
Date: December 12, 2019.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: NIH Director’s Report, ACD
Working Group Reports, Other Business of
the Committee.
Place: National Institutes of Health,
Natcher Building, Conference Room D, 45
Center Drive, Bethesda, MD 20892.
Name of Committee: Advisory Committee
to the Director, National Institutes of Health.
Date: December 13, 2019.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: ACD Working Group Reports,
Other Business of the Committee.
E:\FR\FM\15FEN1.SGM
15FEN1
Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices
Place: National Institutes of Health,
Natcher Building, Conference Room D, 45
Center Drive, Bethesda, MD 20892.
Contact Person: Gretchen Wood, Staff
Assistant, National Institutes of Health,
Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892,
301–496–4272, Woodgs@od.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
acd.od.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: February 11, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02433 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKBBV9HB2PROD with NOTICES
Center for Scientific Review: Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
VerDate Sep<11>2014
19:41 Feb 14, 2019
Jkt 247001
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Drug Discovery and Development.
Date: March 11, 2019.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, Bethesda, MD 20892, 301–435–
1180, ruvinser@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Biology of Retina and Lens.
Date: March 11, 2019.
Time: 1:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Thomas Y. Cho, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–4179,
thomas.cho@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cardiovascular and Surgical
Devices.
Date: March 14–15, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Zoe Fisherman’s Wharf, 425
North Point St, San Francisco, CA 94133.
Contact Person: Jan Li, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5106,
Bethesda, MD 20892, 301.402.9607, Jan.Li@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
4493
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Structural-Functional Cell Biology.
Date: March 25, 2019.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Charles Selden, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187,
MSC 7840, Bethesda, MD 20892, 301–451–
3388, seldens@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Vascular and Hematology.
Date: March 28, 2019.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Larry Pinkus, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892, (301) 435–
1214, pinkusl@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 11, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: February 9, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02422 Filed 2–14–19; 8:45 am]
[FR Doc. 2019–02408 Filed 2–14–19; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 84, Number 32 (Friday, February 15, 2019)]
[Notices]
[Pages 4492-4493]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02433]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of The Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Advisory Committee
to the Director, National Institutes of Health.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Advisory Committee to the Director, National
Institutes of Health.
Date: June 13, 2019.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: NIH Director's Report, ACD Working Group Reports, Other
Business of the Committee.
Place: National Institutes of Health, Natcher Building,
Conference Room D, 45 Center Drive, Bethesda, MD 20892.
Name of Committee: Advisory Committee to the Director, National
Institutes of Health.
Date: June 14, 2019.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: ACD Working Group Reports, Other Business of the
Committee.
Place: National Institutes of Health, Natcher Building,
Conference Room D, 45 Center Drive, Bethesda, MD 20892.
Contact Person: Gretchen Wood, Staff Assistant, National
Institutes of Health, Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892, 301-496-4272,
Woodgs@od.nih.gov.
Name of Committee: Advisory Committee to the Director, National
Institutes of Health
Date: December 12, 2019.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: NIH Director's Report, ACD Working Group Reports, Other
Business of the Committee.
Place: National Institutes of Health, Natcher Building,
Conference Room D, 45 Center Drive, Bethesda, MD 20892.
Name of Committee: Advisory Committee to the Director, National
Institutes of Health.
Date: December 13, 2019.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: ACD Working Group Reports, Other Business of the
Committee.
[[Page 4493]]
Place: National Institutes of Health, Natcher Building,
Conference Room D, 45 Center Drive, Bethesda, MD 20892.
Contact Person: Gretchen Wood, Staff Assistant, National
Institutes of Health, Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892, 301-496-4272,
Woodgs@od.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://acd.od.nih.gov, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: February 11, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-02433 Filed 2-14-19; 8:45 am]
BILLING CODE 4140-01-P
